Amivantamab (Rybrevant)

Targeted TherapyApproved for: NSCLCBiomarker: EGFR exon 20 The FDA has approved amivantamab-vmjw (Rybrevant) as the first treatment for adult patients with non–small cell lung cancer (NSCLC) who harbor EGFR exon 20 insertion mutations. Related Research News Novel drug shows...
|
May 26, 2021
|

Osimertinib (Tagrisso)

Targeted TherapyApproved for: NSCLCBiomarker: EGFR exon 19, exon 21 L858R Osimertinib (Tagrisso) approved Targeted Therapy for non small cell lung cancer (NSCLC) with the biomarker EGFR exon 19, exon 21 L858R. Osimertinib (Tagrisso) is an adjuvant therapy for NSCLC...
|
February 23, 2021
|